Keywords: baxter, acquires, global, rights, xoma, neuprex, acquired

Baxter acquires global rights to Xoma's Neuprex

Article | 27 January 2000

Print This

Baxter has acquired worldwide rights to Xoma Corp's Neuprex(rBPI21) for the treatment of meningococcemia and all future antibacterial and ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in